Legal & General Group
CTXR icon

Legal & General Group’s Citius Pharmaceuticals CTXR Stock Holding History

Legal & General Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-467
Closed -$10.4K – 3440
2024
Q1 		$10.4K Hold
467
– – ﹤0.01% 3190
2023
Q4 		$8.83K Hold
467
– – ﹤0.01% 3260
2023
Q3 		$7.99K Hold
467
– – ﹤0.01% 3307
2023
Q2 		$14K Buy
+467
New +$15.4K ﹤0.01% 3253
2022
Q2 		– Sell
-363
Closed -$16K – 3554
2022
Q1 		$16K Hold
363
– – ﹤0.01% 3287
2021
Q4 		$14K Hold
363
– – ﹤0.01% 3377
2021
Q3 		$18K Hold
363
– – ﹤0.01% 3304
2021
Q2 		$32K Buy
+363
New +$21.8K ﹤0.01% 3107

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's CTXR Position: Q2 2024 in Review

Legal & General Group sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 467 shares — an estimated $10.4K sold.

Legal & General Group first reported a position in CTXR in Q2 2021 and held it in 8 quarters. The position peaked at $32K in Q2 2021. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • Legal & General Group reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 467 Citius Pharmaceuticals shares in Q2 2024, an estimated $10.4K.
  • Legal & General Group first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's Citius Pharmaceuticals position peaked at $32K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.